Drug Search Results
More Filters [+]

Pitrakinra

Alternative Names: pitrakinra
Latest Update: 2023-07-21
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: IL4 Antagonist,IL13 Antagonist

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Aerovance
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pitrakinra

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Dermatitis, Atopic|Asthma

Phase 1: Asthma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

AEROVANT

P2

Completed

Asthma

2010-03-01

PPD/2007/AER 001 DPI/2b

P2

Completed

Asthma

2010-02-01

QGUY/2005/AER 001/-02

P2

Completed

Dermatitis, Atopic

2006-07-01

QGUY/2007/AER 001/-04

P1

Completed

Asthma

None

Recent News Events